Fominaya J, Gasset M, García R, Roncal F, Albar J P, Bernad A
Department of Immunology and Oncology, Centro Nacional de Biotecnología, Universidad Autónoma de Madrid, Spain.
J Gene Med. 2000 Nov-Dec;2(6):455-64. doi: 10.1002/1521-2254(200011/12)2:6<455::AID-JGM145>3.0.CO;2-O.
Due to their chemical definition and reduced size, the use of peptides as gene delivery systems is gaining interest as compared to the more common polymeric non-viral vectors. To achieve gene transfer efficiencies that would make peptides a realistic alternative to existing methods, we have evaluated and attempted to concert those properties with a direct impact on the activity of the system. These considerations have led to the design, synthesis and characterization of a 23-residue cationic peptide which we term RAWA.
We have characterized RAWA biophysically and functionally. Biophysical studies include evaluation of DNA condensation and membrane perturbing activities. DNA transfer activity has been evaluated in cell culture at controlled DNA-to-peptide stoichiometries, using a luciferase gene as reporter. Requirements for additional effectors such as chloroquine and peptide cofactors have also been considered.
RAWA displays in vitro DNA condensing activity similar to that of protamines, reaching maximum effect at a peptide-to-DNA molar charge ratio (CR) of 4 (+/-). The reduced membrane perturbing activity diminishes its cytotoxic potential. In COS-7 cells, transfection efficiency with RAWA peptiplexes, compares favorably with well-recognized systems, including Lipofectamine Plus, Superfect, GenePorter and FuGene. The peptide-associated activity between free and DNA-bound species has been mapped by analyzing dependency on chloroquine treatment. The lack of significant serum inhibition and low toxicity make this system advantageous for potential in vivo application. A ternary complex including the acid-triggered fusogenic JTS-1 peptide is presented as a potential strategy for further in vivo studies.
We have developed a gene delivery system based on an amphipathic cationic peptide with improved DNA condensation ability and reduced cytotoxicity, which maintains membrane binding and perturbing activities. Observed efficiency with this molecule is very high and compares favorably with currently available transfection systems.
由于其化学定义和较小的尺寸,与更常见的聚合物非病毒载体相比,肽作为基因递送系统的应用正受到越来越多的关注。为了实现能使肽成为现有方法的切实可行替代方案的基因转移效率,我们评估并尝试协调那些对系统活性有直接影响的特性。这些考虑促使我们设计、合成并表征了一种23个残基的阳离子肽,我们将其命名为RAWA。
我们对RAWA进行了生物物理和功能表征。生物物理研究包括评估DNA凝聚和膜扰动活性。使用荧光素酶基因作为报告基因,在细胞培养中以受控的DNA与肽化学计量比评估DNA转移活性。还考虑了对其他效应物如氯喹和肽辅因子的需求。
RAWA在体外显示出与鱼精蛋白类似的DNA凝聚活性,在肽与DNA的摩尔电荷比(CR)为4(±)时达到最大效果。降低的膜扰动活性降低了其细胞毒性潜力。在COS-7细胞中,RAWA肽复合物的转染效率与包括Lipofectamine Plus、Superfect、GenePorter和FuGene在内的公认系统相比具有优势。通过分析对氯喹处理的依赖性,绘制了游离和与DNA结合的物种之间的肽相关活性。缺乏显著的血清抑制和低毒性使该系统有利于潜在的体内应用。一种包含酸触发的融合肽JTS-1的三元复合物被提出作为进一步体内研究的潜在策略。
我们开发了一种基于两亲性阳离子肽的基因递送系统,具有改进的DNA凝聚能力和降低的细胞毒性,同时保持膜结合和扰动活性。观察到该分子的效率非常高,与目前可用的转染系统相比具有优势。